

VI. Segment Information *

(Billions of Yen)

	FY09	FY10	FY11	FY12	vs. FY11	increase/ decrease
Net Sales	1,466.0	1,419.4	1,508.9	1,557.3	48.3	3.2%
Ethical drugs	1,317.7	1,267.4	1,358.8	1,401.7	42.9	3.2%
Japan	548.9	578.5	592.2	588.4	-3.8	-0.6%
Overseas	768.9	689.0	766.6	813.3	46.8	6.1%
Consumer healthcare	58.2	60.3	61.7	66.9	5.2	8.4%
Others	94.8	96.3	93.1	93.1	0.0	0.0%
Adjustments	-4.8	-4.6	-4.6	-4.4	0.2	
Operating Income	420.2	367.1	265.0	122.5	-142.5	-53.8%
Ethical drugs	400.6	346.0	243.8	99.0	-144.7	-59.4%
Consumer healthcare	11.0	12.2	11.8	13.2	1.3	11.4%
Others	10.8	11.0	11.7	12.4	0.7	6.0%
Adjustments	-2.2	-2.2	-2.2	-2.1	0.2	

(Billions of Yen)

	FY09	FY10	FY11	FY12	vs. FY11	increase/ decrease
Capital expenditures	114.5	148.9	1,255.2	283.3	-971.9	-77.4%
Ethical drugs	110.6	144.7	** 1,249.1	*** 275.6	-973.5	-77.9%
Consumer healthcare	0.5	0.4	0.7	0.7	0.0	1.0%
Others	3.4	3.7	5.4	7.0	1.7	30.8%
Adjustment	-	-	-	-	-	

** Including increase of intangible assets and goodwill due to acquisition of Nycomed.

*** Including increase of intangible assets and goodwill due to acquisition of URL Pharma, Multilab, LigoCyte and Envoy.

Depreciation	98.7	91.5	126.9	165.5	38.7	30.5%
Ethical drugs	93.0	86.1	121.7	160.1	38.4	31.5%
Consumer healthcare	0.8	0.8	0.8	0.8	-0.0	-4.2%
Others	5.6	5.2	4.9	5.2	0.3	5.7%
Adjustment	-0.7	-0.6	-0.6	-0.5	0.0	

Amortization of goodwill	15.1	14.1	22.2	34.4	12.2	55.0%
Ethical drugs	14.6	13.7	22.1	34.4	12.3	55.8%
Consumer healthcare	-	-	-	-	-	-
Others	0.5	0.5	0.1	0.0	-0.1	-95.8%
Adjustment	-	-	-	-	-	

* Effective from the FY10, the Accounting Standard for Disclosures about Segments of an Enterprise and Related Information has been adopted. The figures for "FY09" are calculated and indicated after applying the accounting standard.